Merrimack Pharmaceuticals (MACK) PT Lowered to $4 at Baird as MM-121 Disappoints

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. AXP
9. TMUS
10. SPY

Go back to Merrimack Pharmaceuticals (MACK) PT Lowered to $4 at Baird as MM-121 Disappoints

Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility

October 19, 2018 6:00 AM EDT

CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC.

This decision was made in agreement with the Chair of the independent Data Safety Monitoring Board following an interim analysis that was triggered by the occurrence of 75% of events required for trial completion. In total, 88% (67/76) of required events were captured in this analysis, and while the... More